End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
297 CNY | +1.31% | +6.26% | +0.91% |
04-24 | Imeik Technology Development Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-20 | Imeik Technology Development's Profit Rises 47% on Higher Revenue | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.91% | 8.82B | C | ||
+12.07% | 128B | A- | ||
-9.04% | 10.65B | A- | ||
+16.72% | 7.19B | C | ||
+25.15% | 4.99B | B+ | ||
+7.17% | 3.4B | C- | ||
-1.36% | 3.03B | B- | ||
-8.73% | 2.14B | - | - | |
-10.15% | 2B | - | ||
-22.81% | 1.79B | - | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300896 Stock
- Ratings Imeik Technology Development Co.,Ltd.